With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

据该公司介绍，四名接受100万细胞剂量zugo-cel治疗的自身免疫疾病患者显示出持续至少28天的深度B细胞消减。所有患者在28天评估时均表现出显著的临床改善，其中一名系统性红斑狼疮 (SLE)患者在治疗后六个月内达到缓解。

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Gene editing for sickle-cell is here. This is how researchers knew what DNA to change. The world’s first commercial gene-editing treatment is set to start changing the lives of people with sickle-cell ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Forbes contributors publish independent expert analyses and insights. Peter Bendor-Samuel is founder & executive chairman of Everest Group. One of the SciTech trends I’m currently paying attention to ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...